Drug Profile
CGS 24565
Latest Information Update: 20 May 1999
Price :
$50
*
At a glance
- Originator Novartis
- Class Antihyperlipidaemics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
Most Recent Events
- 20 May 1999 No-Development-Reported for Hyperlipidaemia in Switzerland (Unknown route)